Chemotherapy-induced nausea is one of the most distressing symptoms reported by patients undergoing treatment, and even with the introduction of newer antiemetics such as ondansetron and aprepitant, nausea remains
problematic in the clinic. Indeed, when acute nausea is not properly managed, the cues of the clinic can become
associated with this distressing symptom resulting in anticipatory nausea for which no effective treatments are
available. Clinical trials exploring the potential of exogenous or endogenous cannabinoids to reduce
chemotherapy-induced nausea are sparse; therefore, we must rely on the data from pre-clinical rat models
of nausea. In this review, we explore the human and pre-clinical animal literature examining the potential for
exogenous and endogenous cannabinoid treatments to regulate chemotherapy-induced nausea. The preclinical evidence points to a compelling need to evaluate the antinausea potential of cannabidiol, cannabidiolic
acid, and treatments that boost the functioning of the endocannabinoid system in human clinical trials.